Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXPEDITORS INTERNATIONAL OF WASHINGTON INCEXPD · Entity 3192 | Director | August 06, 2026 | August 07, 2026 |
| Ingevity CorpNGVT · Entity 4401 | Director | April 30, 2026 | May 01, 2026 |
| Keenova Therapeutics plcMNK · Entity 28960 | Director | March 01, 2018 | March 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXPEDITORS INTERNATIONAL OF WASHINGTON INC
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 23,141 |
Reported balance
After 2026-08-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-06 · Gift · Disposed 1,400 · Balance 23,141 F1: The transaction reported involved a gift by the reporting person of 1,400 shares of common stock to a charitable fund. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported involved a gift by the reporting person of 1,400 shares of common stock to a charitable fund.
Ingevity Corp
Report date April 30, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,788 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 1,904 · Balance 14,788 F1: Grant of restricted stock units pursuant to Ingevity Corporation's 2025 Omnibus Incentive Plan, which will vest in full on April 30, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 3,747 |
Reported balance
Holding disclosure · report date 2026-04-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,747 F2: Held through the Diane H. Gulyas Trust, of which the reporting person is trustee and the reporting person's spouse is beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units pursuant to Ingevity Corporation's 2025 Omnibus Incentive Plan, which will vest in full on April 30, 2027.
F2: Held through the Diane H. Gulyas Trust, of which the reporting person is trustee and the reporting person's spouse is beneficiary.
Keenova Therapeutics plc
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,344 |
Reported balance
After 2018-03-01 transaction · row 1
1 source rowRow 1 · 2018-03-01 · Tax withholding · Disposed 2,576 · Balance 17,344 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
W R GRACE & CO
Report date September 22, 2021 · Filed September 22, 2021
Section 16 reporting ended · disclosed 2021-09-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-09-22 transaction · row 1
1 source rowRow 1 · 2021-09-22 · Disposition to issuer · Disposed 14,823 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement & Plan of Merger (the "Merger Agreement"), dated April 26, 2021, among W. R. Grace & Co. ("Company"), W. R. Grace Holdings LLC (fka Gibraltar Acquisition Holdings LLC), a Delaware limited liability company ("Parent"), and Gibraltar Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on April 26, 2021, pursuant to which on Sept. 22, 2021, Merger Sub merged with and into the Company (the "Merger") and pursuant to which the Company survived the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each issued & outstanding share of Company common stock was cancelled and converted into the right to receive $70.00 in cash (the "Merger Consideration") without interest, subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement & Plan of Merger (the "Merger Agreement"), dated April 26, 2021, among W. R. Grace & Co. ("Company"), W. R. Grace Holdings LLC (fka Gibraltar Acquisition Holdings LLC), a Delaware limited liability company ("Parent"), and Gibraltar Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on April 26, 2021, pursuant to which on Sept. 22, 2021, Merger Sub merged with and into the Company (the "Merger") and pursuant to which the Company survived the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each issued & outstanding share of Company common stock was cancelled and converted into the right to receive $70.00 in cash (the "Merger Consideration") without interest, subject to withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2017 Filed May 10, 2017 16:40 UTC | W R GRACE & CO GRA · Entity 135295 | GrantCommon Stock, par value $0.01 per share | 1,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001045309-17-000059 · wf-form4_149444883716103.xml · nonDerivative · entry 1 Gulyas Diane H. · CIK 0001466674 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,850 F1 · security: Each share of Common Stock also represents one Preferred Stock Purchase Right. Each such Right entitles the holder to purchase Preferred Stock or other securities or property upon the occurrence of certain events and subject to certain conditions. F2 · price: Issued in partial payment for 2017 retainer. Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 00:02 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,286 | $51.55 | $117,843.30 |
DisclosureSEC source: 0000950138-17-000269 · edgar.xml · nonDerivative · entry 2 Gulyas Diane H. · CIK 0001466674 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,896 Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 00:02 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 5,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000269 · edgar.xml · nonDerivative · entry 1 Gulyas Diane H. · CIK 0001466674 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,182 F1 · shares: Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 12:58 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 1,057 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-16-001371 · edgar.xml · nonDerivative · entry 1 Gulyas Diane H. · CIK 0001466674 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,459 F1 · shares: Consists of restricted stock units that vest in their entirety as of October 1, 2017. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.